43 results about "Muscle disease" patented technology

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.

The present invention relates to the effect of promoting muscle development and growth through inhibition of the expression of MRF4. According to the present invention, MRF4 isolated and identified from skeletal muscles of Nile tilapia showed a strong association with MyoG and MEF2 proteins, and the expression of MyoG and MEF2 was found to significantly increase when the MRF4 gene was disrupted through CRISPR / Cas9 gene editing, and thus the present invention has the effect of being able to be used for the promotion of muscle development or the treatment of muscle diseases through the inhibition of the MRF4 gene.

The present invention relates to a composition for the prevention or treatment of muscle diseases comprising an extract of Aralia elata. The Aralia elata extract of the present invention has the effect of enhancing grip strength, increasing muscle weight, and improving exercise performance.

The present invention relates to a mechanism that enables persons with a muscular disease to open the door, which can be used in places where people with muscular diseases are present, such as hospitals, health centers or places that are publicly accessible in daily life, characterized in that it comprises a door handle (2) for opening the door (1), a connecting shaft (3) attached to the end of the door handle (2), a power storage device (4) located on the door (1) which contains a battery and a motor-driven roller, a motion sensor (5) arranged on the power storage device (4) which detects the human hand, a touch sensor (6) which is attached to the door handle (2) and detects when the door handle (2) is held, and a steel cable (7) of which one end is connected to the connecting shaft (3) and of which the other end is connected to the roller in the power storage device (4).

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

The present invention relates to the use of a hemp seed extract for preventing or ameliorating muscle diseases by promoting myoblast differentiation or muscle regeneration. In the present invention, the hemp seed extract may exhibit preventive or therapeutic effects on various muscle diseases by increasing muscle mass, strengthening muscle power, improving muscle function, and enhancing exercise performance, and also has an effect of improving muscle function in healthy individuals in addition to treating muscle diseases.

The present invention relates to a composition for preventing, alleviating, or treating muscle diseases, the composition comprising an NFAT inhibitor as an active ingredient. An NFAT inhibitor (VIVIT peptide) comprising the amino acid sequence of SEQ ID NO: 1 according to the present invention was found to: alleviate the inhibition of muscle differentiation by suppressing NFAT signaling pathway activation induced by excessive calcium exposure, and increase the expression levels of muscle differentiation-related proteins in C2C12 myoblasts and mouse muscle-derived myoblasts. Thus, the NFAT inhibitor can be effectively used as a composition for preventing, alleviating, or treating muscle diseases.

The present invention relates to a composition for increasing muscle mass, improving muscle function, or preventing or treating muscle disease, comprising Phocaeicola vulgatus or cultures thereof. In addition, the present invention relates to a method for increasing muscle mass, improving muscle function,, or preventing or treating muscular disease, comprising administering or taking a composition comprising Phocaeicola vulgatus or a culture thereof as an active ingredient to an individual in need. The Phocaeicola vulgatus of the present invention has the outstanding effect of increasing muscle strength, increasing muscle weight, and increasing muscle fiber.

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain or muscle). Methods for treating various diseases or disorders, such as neurological diseases or muscular diseases, with the conjugates are provided.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases. Specifically, the elderberry extract or monosaccharide and amino acid combined compound disclosed by the invention inhibits apoptosis of muscle cells, inhibits expression of inflammatory cytokines, promotes secretion of testosterone and inhibits expression of amyotrophy marker protein and myogenesis inhibition protein, and shows an effect of recovering muscle in a sarcopenia animal model; therefore, the device can be effectively used in the treatment of muscle diseases.

The present invention relates to methods and compositions for treating muscle diseases and disorders. The invention provides methods for treating muscle myopathies, including muscular dystrophy and cardiomyopathy, by administering stable, long-acting therapeutic agents for vasoactive intestinal peptides. These agents include one or more elastin-like peptides and can be administered at low doses.

The invention discloses a muscle disease auxiliary exercise device, and relates to the technical field of muscle auxiliary exercise devices, the muscle disease auxiliary exercise device comprises an exercise table, a back cushion is arranged at the top end of the exercise table, the exercise table performs exercise operation on legs of a patient through an exercise mechanism, and an adjusting mechanism is arranged. By arranging the exercise mechanism, a patient lies on an exercise table, the shanks of the patient are bound to a supporting plate through binding bands, the knees of the patient are located at one end of the supporting plate, and the position of the supporting plate is adjusted, so that the distance between a first connecting shaft and one end of the supporting plate is equal to the length of the thighs of the patient; the motor runs to drive the first rotating frame and the second rotating frame to rotate synchronously, and the first rotating frame and the second rotating frame rotate synchronously to drive the supporting plate to move horizontally and upwards, so that the feet of the patient are lifted, and the patient is helped to exercise the legs conveniently.

The application discloses a neuromuscular function evaluation system and relates to the field of biomedical engineering.The system comprises a lower limb isometric muscle strength measuring device, an electromyographic signal acquisition device, a synchronous control module and an upper computer system, the upper computer system realizes real-time synchronous acquisition of muscle strength and electromyographic signals through the synchronous control module, and accurately captures neuromuscular activation and response processes.After the collected data is preprocessed, muscle strength peak value, force development rate, neuromuscular activation delay and electromyographic time-frequency domain parameters and various characteristics are extracted.A machine learning model is constructed by using the extracted characteristics, and is used for evaluation of the neuromuscular function state.The application improves the accuracy and automation degree of neuromuscular function evaluation through an objective evaluation mode, and is particularly suitable for function evaluation and rehabilitation monitoring of multiple types of people, such as the elderly, people with neuromuscular diseases, rehabilitation personnel after nerve injury or sports injury, etc.

The invention discloses application of S-adenosylhomocysteine in preparation of a medicine for treating neuromuscular diseases, and belongs to the technical field of medicines. The invention discloses a novel pharmaceutical application of S-adenosine homocysteine in preparation of drugs for treating neuromuscular diseases for the first time. Mechanism research finds that S-adenosylhomocysteine can enhance the ability of a Trmt61a / 6 compound to bind unmethylated tRNA and inhibit abnormal interaction between CMT2 pathogenic mutant protein and stress particle core protein, so that the ability of motor neurons to resist external stress is enhanced, and the S-adenosylhomocysteine has the effects of improving peripheral nerve and muscle lesions of neuromuscular diseases, improving the immunity of the motor neurons and improving the immunity of the motor neurons. And the potential of motor nerve dysfunction. The invention provides a direction for new clinical application of the S-adenosyl homocysteine. The invention provides possibility for preparing novel medicines for treating neuromuscular diseases.

The present disclosure relates to a pharmaceutical composition for preventing or treating muscle diseases. Particularly, an elderberry extract or a monosaccharide- and amino acid-coupled compound, according to the present disclosure exhibits the effects of inhibiting muscle cell apoptosis, inhibiting the expression of inflammatory cytokines, promoting the secretion of testosterone, inhibiting the expression of muscle atrophy markers and myostatin and causing muscle to recover in sarcopenia animal models, and thus can be effectively used in the treatment of muscle diseases.

This invention discloses a targeted MSTN The sgRNA of the gene and its application in constructing a feline myostatin gene knockout model; the targeted MSTN The nucleotide sequence of the gene's sgRNA is shown in SEQ ID NO.1 and / or SEQ ID NO.2. This invention systematically establishes a CRISPR / Cas9 genome editing platform suitable for domestic cats for the first time and successfully constructs the world's first... MSTN The gene knockout live model in domestic cats represents a breakthrough in the technical barriers to functional gene research in domestic cats. It has been demonstrated that sgRNA is a highly efficient editing tool for the MSTN gene in domestic cats. The constructed... MSTN The gene knockout domestic cat model provides an unprecedented tool for in-depth research on muscle biology and muscle diseases in mammalian (cat) systems that are more closely related to humans. It fills the gap in large animal models in this field and has significant value for basic scientific research and translational medicine.

The present invention relates to methods of using quantitative colocalization assays to assess the functionality of cellular molecules in muscle cells, to assess the efficacy of a compound to modulate the functionality of cellular molecules in muscle cells, to predict the ability of a compound to treat a muscle disease, to monitor the response of a patient suffering from a muscle disease to a therapeutic compound, to select a patient suffering from a muscle disease for treatment with a therapeutic compound, or to determine whether a patient suffering from a muscle disease is likely to benefit from treatment with a therapeutic compound.

The invention discloses application of nucleoside compounds in preparation of drugs for treating neuromuscular diseases, and belongs to the technical field of medicines. The invention discloses a novel pharmaceutical application of the nucleoside compound in preparation of drugs for treating neuromuscular diseases for the first time. Research finds that the nucleoside compound can enhance the ability of a Trmt61a / 6 compound to bind unmethylated tRNA and inhibit abnormal interaction between pathogenic mutant protein and stress particle core protein, so that peripheral nerve and muscle lesions of neuromuscular diseases and motor nerve dysfunction are improved. The invention provides a direction for new clinical application of nucleoside drugs. The invention provides possibility for preparing novel medicines for treating neuromuscular diseases.

Described herein are polypeptides comprising an FGF17, IGF2, or BMP7 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and / or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and / or synergistic compositions.

The present disclosure provides a muscle-specific chimeric promoter, including: (1) a hybrid α-myosin heavy chain enhancer / muscle creatine kinase enhancer-promoter (MHCK7 promoter); and (2) one or more binding sites of a transcription factor, wherein the MHCK7 promoter includes the sequence set forth in SEQ ID NO: 2 or a functional variant thereof having at least 90% sequence identity to SEQ ID NO: 2, and wherein the transcription factor is a member selected from the group consisting of the MyoD family of transcription factors. Compared with the MHCK7 promoter, the specificity and expression ability in muscle tissue of the muscle-specific chimeric promoter provided in the present application are significantly improved. The application of the muscle-specific chimeric promoter in mammals and muscle cells is of great significance for the treatment of muscle diseases.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

The present invention relates to a novel use of a CXCL5 inhibitor and a novel antibody or antigen-binding fragment thereof usable as a CXCL5 inhibitor. The novel use of a CXCL5 inhibitor and the novel antibody or antigen-binding fragment thereof usable as a CXCL5 inhibitor of the present invention enable the treatment or prevention of cancer cachexia or muscle disease, enable cancer cachexia or muscle disease to be diagnosed with high efficiency, and enable a drug for the treatment or prevention of cancer cachexia or muscle disease to be screened with high efficiency.

The present invention relates to: a method for preparing a chiral gamma lactam derivative or a pharmaceutically acceptable salt thereof by using a chiral organocatalytic compound; and a composition for preventing, alleviating or treating muscle diseases, mental diseases, or neurodegenerative diseases, comprising the derivative or the pharmaceutically acceptable salt thereof. The chiral gamma lactam derivative or the pharmaceutically acceptable salt thereof, of the present invention, has an effect of inhibiting MAO-B and MSTN, targets D1-mClu5, and can be used in the prevention, alleviation, or treatment of muscle diseases including sarcopenia, mental diseases including depression, neurodegenerative diseases including Parkinson's disease, and the like.

The present invention relates to a pharmaceutical composition comprising a supercritical cannabis extract for preventing or treating muscle diseases, and, more specifically, to a pharmaceutical composition comprising a supercritical cannabis extract, thereby exhibiting effects of inhibiting muscle cell death, protecting muscle cells, promoting muscle cell differentiation and alleviating muscle inflammation.

The present invention relates to a composition for the prevention or treatment of muscle diseases comprising an extract of Aralia elata. The Aralia elata extract of the present invention has the effect of enhancing grip strength, increasing muscle weight, and improving exercise performance.

Muscle targeting complexes and uses thereof. Some aspects of the present disclosure relate to complexes comprising a muscle targeting agent covalently linked to a molecular load. In some embodiments, the muscle targeting agent specifically binds to an internalized cell surface receptor on a muscle cell. In some embodiments, the molecular load inhibits the activity of disease alleles associated with muscle disease. In some embodiments, the molecular load is an oligonucleotide, such as an antisense oligonucleotide or an RNAi oligonucleotide.

The present invention relates to a variable domain (VHH) of a camelid heavy chain molecule that binds to TfR, and its use, for example, to transport a therapeutic molecule to muscle cells in a typically pathological state.

Provided herein are oligonucleotides, bicyclic peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.